Carbon Biosciences emerges with a new viral vector to shake up the cystic fibrosis gene therapy field
Carbon Biosciences wants to disrupt the field of AAV gene therapy by tapping into a family of thousands of viruses to find ones that allow for the “next generation of viral delivery vehicles,” as CEO Joel Schneider puts it.
The Massachusetts biotech emerged Tuesday with $38 million in partnership with the Cystic Fibrosis Foundation to take a bocavirus-based — part of the broader parvovirus web — gene therapy into the clinic for the lung disorder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.